尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。
Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
晚期6小时纤溶酶原激活剂没有减少梗死体积，而是更坏出血性转换。
Late 6-hour tPA did not decrease infarction but instead worsened hemorrhagic conversion.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
目的观察应用重组组织型纤溶酶原激活剂溶栓治疗急性心肌梗死的效果。
Objective to observe the effect of recombinant tissue plasminogen activator in the treatment of acute myocardial infarction.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
目的探讨急性冠状动脉综合征患者内皮组织纤溶酶原激活剂储备功能的变化规律。
Objective To study the changes of the endothelial tissue plasminogen activator reserve capacity in patients with acute coronary syndromes.
目的：探讨尿激酶型纤溶酶原激活因子的蛋白表达与上皮性卵巢癌生物学行为的关系。
Objective: To identify the significance of urokinase-type plasminogen activator expression in patients with epithelial ovarian carcinoma.
目的：研究重组纤溶酶原激活剂抑制剂-2基因表达对纤维肉瘤细胞超微结构的影响。
The effect of recombinant PAI-2 on the ultrastructure of fibrosarcoma-transplanted tumor was investigated in this study.
目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。
Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).
纤溶酶原激活物抑制剂1 (PAI - 1)是一种单链糖蛋白，起抑制纤溶活性的作用。
Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
目的探讨纤溶酶原激活物抑制物-1（PAI- 1）启动子区基因多态性与脑卒中的关系。
Objective To investigate the relationship between the plasminogen activator inhibitor 1(PAI 1) promotor region gene polymorphism and cerebral stroke.
用酶联免疫吸附法检测血浆血管性假性血友病因子、凝血酶调节蛋白、纤溶酶原激活物抑制物1水平。
The von Willebrand's disease factors in plasm, adjusted protein of thrombase and inhibitor 1 of activator of plasminogen were detected with enzyme-linked immunosorbent assay.
以上结果说明，小鼠胚胎着床过程中胰蛋白酶及纤溶酶原激活因子等水解蛋白酶的活性起着重要作用。
These results suggested that proteolytic activities were involved in implantation, some proteinases such as trypsin and plasminogen activator had important functions during trophoblast invasion.
目的：观察小剂量长疗程尿纤溶酶原激活物(u - PA)治疗不稳定型心绞痛(uap)的临床疗效。
Objective: to investigate the clinical effectiveness of prolonged low-dose urine plasminogen activator (u-PA) therapy in patients with unstable angina pectoris (UAP).
目的探讨缺血-再灌注对大鼠视网膜分泌组织型纤溶酶原激活物(TPA)的影响及其与视网膜水肿的关系。
Objective to explore the relationship between the activity change of tissue type plasminogen activator (TPA) of retinas and retinal edema in retinal ischemia and reperfusion rats.
目的研究前炎症细胞因子对人胸膜间皮细胞（HPMC）释放纤溶酶原激活物抑制剂（PAI1）的诱导效应。
Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(PAI 1) by human pleural mesothelial cells(HPMC).
目的观察罗格列酮对2型糖尿病患者血脂水平和血浆纤溶酶原激活物抑制剂1 (PAI - 1)活性的影响。
Objective To investigate the influence of rosiglitazone on blood lipids and plasma PAI-1 activity in type 2 diabetic patients.
为探讨纤溶酶原激活物抑制因子1（PAI 1）在肾损伤后纤维化中的作用和意义，揭示其发病的分子病理机制。
ObjectiveTo study the role and significance of plasminogen activator inhibitor-1(PAI-1) in renal fibrosis(RF) after damage and elucidate the molecular pathogenetic mechanisms of RF.
目的探讨血浆组织型纤溶酶原激活物(t -PA)及其抑制物(PAI - 1)在急性脑梗死发病中的意义。
Objective To assess the clinical significance of plasma t-PA, PAI-1 in acute cerebral infarction.
本文用尿激酶(UK)和人体组织型纤溶酶原激活剂(t - PA)进行了兔髂股动脉血栓实验性溶解的对照研究。
The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.
公众应当认识到，只有食品和药物管理局核准的中风治疗药物(组织型纤溶酶原激活剂)必须在症状出现的3小时内给予。
The public should be aware that the only Food and Drug Administration-approved stroke treatment medication must be administered within 3 hours of symptom onset.
目的研究沙鼠脑缺血再灌注后脑内1型纤溶酶原激活物抑制剂(PAI - 1)蛋白表达变化，以及西比灵干预的影响。
Objective to study the effects of transient cerebral ischemic reperfusion (IR) and flunarizine on the expression of plasminogen activator inhibitor-1 (PAI-1) protein in brain tissue of gerbils.
目的：探讨纤溶酶原激活物抑制物-1 (PAI - 1)活性变化和其基因多态性对脑梗死及其再梗死发病的关系。
To investigate the changes of plasma PAI 1 activity and its gene polymorphism in cerebral infarction.
目的：观察银杏叶提取物对2型糖尿病病人纤溶酶原激活物抑制物1（PAI 1）及凝血烷B2（TXB 2 ）的影响。
AIM: To observe the effect of extract of Ginkgo biloba leaves on plasminogen activator inhibitor 1(PAI-1)and thromboxane B2(TXB-2)in type 2 diabetes mellitus(DM).
方法：检测33例糖尿病肾病患者及30例健康体检对照组血浆纤溶酶原激活物抑制物-1（PAI-1），观察检测结果。
Method Plasminogen activator inhibitor-1(PAI-1) in 33 cases of diabetic nephropathy and 30 healthy controls were detected, and the test results were observed.
纤溶酶原激活物抑制物1 (PAI - 1)是血浆纤维蛋白溶解系统的重要组成物之一，对维持血浆纤溶系统的稳定起重要作用。
Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.
从脑片染色结果及给药后不同时间点大鼠血液中纤溶酶原激活剂和其抑制剂的含量变化显示用该工艺纯化的蚓激酶有较好的溶栓作用。
The EFE purified through the process mentioned above has high specific activity and good effect in treating cerebral ischemia. Concerntration oft-PA and PAI, in respect of the rats in…
目的：探讨急性冠脉综合征患者应用阿托伐他汀调脂治疗后对血管内皮舒张功能、血浆纤溶酶原激活物抑制物1及血管内皮素1的影响。
Objective To study the effects of atorvastatin cholesterol-lowering therapy on vascular endothelial function and plasminogen activator inhibitor-1 in acute coronary syndromes.
据报道，纳豆激酶有和胞浆素一样的可直接分解纤维蛋白的生物特性，或者增强尿激酶原和t—PA(人组织型纤溶酶原激活剂)的活性。
According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).
据报道，纳豆激酶有和胞浆素一样的可直接分解纤维蛋白的生物特性，或者增强尿激酶原和t—PA(人组织型纤溶酶原激活剂)的活性。
According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).
应用推荐